Congolese authorities have authorised clinical trials for four experimental Ebola treatments, which will allow researchers to collect valuable data about their effectiveness, the health ministry said on Saturday.
The ministry said health workers have already administered therapeutic treatments to more than 150 Ebola patients since August in an effort to contain the worst of Democratic Republic of Congo’s 10 outbreaks of the hemorrhagic fever since 1976.
But until now doctors have decided which treatment to use on a case-by-case basis.
In the clinical trial, the choice of treatment will now be randomised.
The health ministry said treatment will still be free of charge.
“Precious information about the effectiveness of the treatments obtained during the clinical trial will allow for the development of these treatments on a wider scale to save more lives,” the ministry said.
The four treatments are mAb114, which was developed by the U.S. government; ZMapp, an intravenous treatment made by Mapp Biopharmaceutical; Remdesivir, made by Gilead Sciences; and Regeneron’s REGN-EB3.
As of November 18, 151 patients had received one of the four drugs.
Of those, 76 had recovered, 44 died and 31 were still hospitalised — a mortality rate of 37 per cent.
By contrast, among those who had not received treatment, the mortality rate was close to 80 per cent.
The ministry said that the data from the current outbreak would probably not be sufficient to make definitive conclusions about the effectiveness of the treatments and that the trials could continue during future outbreaks.
In spite of the use of the treatments as well as an experimental vaccine manufactured by Merc.
The authorities have struggled to contain the outbreak due to widespread militia violence in eastern Congo and community resistance to health workers.
At least 228 people are believed to have died, and the World Health Organisation said on Nov. 19 that it expects the outbreak to last at least another six months. (Reuters/NAN)
Support PREMIUM TIMES' journalism of integrity and credibility
Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.
For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.
By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.
TEXT AD: To advertise here . Call Willie +2347088095401...